Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
103

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Epilepsy surgery in pediatric patients with complex COL4A1/2-associated epilepsy.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Approved Targeted Treatments for Pediatric Brain Tumors.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

A two-step temporal data augmentation and supervised learning framework for predicting autism diagnosis at 36 months in patients with tuberous sclerosis complex.

Computers in biology and medicine·2026
Same author

Genomic modifiers of malignant and neurodevelopmental phenotypes in individuals with PTEN hamartoma tumor syndrome.

NPJ genomic medicine·2026
Same author

Tuberous sclerosis complex.

Nature reviews. Disease primers·2026
Same author

Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes.

Pediatric neurology·2026
Same journal

Association of Cerebrospinal Fluid-Restricted Oligoclonal Bands With Relapsing Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Pediatric neurology·2026
Same journal

Variable Phenotype in Three Siblings With RAN Binding Protein 2 Variant With Potential Preventive Treatment for Recurrences.

Pediatric neurology·2026
Same journal

Corrigendum to Temporary Pacemaker in a Pediatric Guillain-Barré Case With Life-Threatening Bradyarrhythmia Pediatr Neurol 177 (2026) 109-110. doi: 10.1016/j.pediatrneurol.2026.01.015.

Pediatric neurology·2026
Same journal

Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease).

Pediatric neurology·2026
Same journal

Examining Epilepsy in Angelman Syndrome: Insights From Caregiver-Reported Data in the Linking Angelman and Dup15q Data for Expanded Research Database.

Pediatric neurology·2026
Same journal

Impact of Postpandemic Pediatric Infection Rebound on Febrile Seizures: A Nationwide Cohort Study, 2013-2023.

Pediatric neurology·2026
查看所有相关文章

相关实验视频

Updated: Jun 12, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K

拉帕米辛抑制剂的目标哺乳动物水平在博治疗下降

Lena-Luise Becker1, Karen Agricola2, David M Ritter2

  • 1Institute of Cell Biology and Neurobiology, Department of Pediatric Neurology, Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Pediatric neurology
|September 21, 2024
PubMed
概括
此摘要是机器生成的。

在瘤硬化综合体 (TSC) 患者中,使用乳腺胺抑制剂 (mTORi) 向哺乳动物的塞诺巴马特导致埃弗罗利斯水平显著下降. 建议监测mTORi水平,当与cenobamate同时使用时.

关键词:
基酸盐 (Cenobamate) 是一种这是Everolimus.这就是西罗利木斯.结核性硬化综合体 结核性硬化综合体这是一种mTOR抑制剂.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

相关实验视频

Last Updated: Jun 12, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 神经学 神经学
  • 在瘤学瘤学.

背景情况:

  • 埃弗罗利莫斯已批准用于治疗结核性硬化综合体 (TSC) 的耐药性.
  • 塞诺巴马特是一种较新的抗发作药物,在TSC患者中越来越多地使用.
  • 塞诺巴酸盐与哺乳动物目标拉巴胺抑制剂 (mTORi) 之间的潜在药物相互作用尚未得到充分研究.

研究的目的:

  • 评估赛诺巴马酸对TSC患者mTORi血清药物水平的影响.
  • 为了研究博和mtori之间的潜在药物相互作用.

主要方法:

  • 对20名TSC患者的回顾性分析.
  • 药物水平mTORi (everolimus或sirolimus) 的比较,在开始使用cenobamate之前和之后.

主要成果:

  • 在开始服用雪诺巴马特后,Everolimus水平显著下降 (P=0.01221).
  • 斯洛利慕斯水平没有显著变化 (P=0.3828).
  • 塞诺巴在控制发作方面表现出不同程度的有效性,10%的患者实现了无发作.

结论:

  • 在TSC患者中,Cenobamate的启动会导致Everolimus水平降低,这可能是由于CYP3A4的诱导.
  • 建议监测mTORi血清度和调整剂量,当与cenobamate.